Khateeb, M., Hameed, D., Moeen, A., Salah, T., Behnsawy, H., Abdelsalam, Y., Shehata, S., El-Akkad, M. (2017). Evaluation of Neoadjuvant Chemotherapy in Treatment of Muscle Invasive Urothelial Bladder Tumors in Upper Egypt. Research in Oncology, 13(2), 46-50. doi: 10.21608/resoncol.2017.1246.1029
Mohamed Khateeb; Diaa Hameed; Ahmed Moeen; Tareq Salah; Hosney Behnsawy; Yasser Abdelsalam; Samir Shehata; Magdi El-Akkad. "Evaluation of Neoadjuvant Chemotherapy in Treatment of Muscle Invasive Urothelial Bladder Tumors in Upper Egypt". Research in Oncology, 13, 2, 2017, 46-50. doi: 10.21608/resoncol.2017.1246.1029
Khateeb, M., Hameed, D., Moeen, A., Salah, T., Behnsawy, H., Abdelsalam, Y., Shehata, S., El-Akkad, M. (2017). 'Evaluation of Neoadjuvant Chemotherapy in Treatment of Muscle Invasive Urothelial Bladder Tumors in Upper Egypt', Research in Oncology, 13(2), pp. 46-50. doi: 10.21608/resoncol.2017.1246.1029
Khateeb, M., Hameed, D., Moeen, A., Salah, T., Behnsawy, H., Abdelsalam, Y., Shehata, S., El-Akkad, M. Evaluation of Neoadjuvant Chemotherapy in Treatment of Muscle Invasive Urothelial Bladder Tumors in Upper Egypt. Research in Oncology, 2017; 13(2): 46-50. doi: 10.21608/resoncol.2017.1246.1029
Evaluation of Neoadjuvant Chemotherapy in Treatment of Muscle Invasive Urothelial Bladder Tumors in Upper Egypt
1Urology University Hospital, Faculty of Medicine, Assiut University, Assiut, Egypt
2Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Assiut University, Assiut, Egypt
Abstract
Background: Bladder cancer is a common health problem is Egypt where it is the 3rd common cancer (6.9%) in both sexes and the 2nd common (10.7%) among males. Neoadjuvant chemotherapy has proven benefits in treatment of muscle invasive bladder cancer (MIBC), yet it is still underutilized. Aim: To study the response to neoadjuvant chemotherapy in patients with MIBC and their attitude towards definitive treatment after completion of neoadjuvant therapy. Methods: In this prospective study, 85 patients with MIBC were recruited between September 2013 and September 2014. They were scheduled to receive three cycles of gemcitabine (1000 mg/m2, on days 1 and 8) plus cisplatin (75 mg/m2 on day 1) or carboplatin (AUC=5 on day 1) in patients with impaired renal function prior to definitive treatment. Results: Sixty-seven patients were evaluable for response and toxicity. The majority (79%) were males and their median age was 61 years (range: 38-84). The initial T stage was T3 or T4 in 72% of patients. Complete response was documented in 6 (9%) patients, partial response in 41 (61.2%), stationary disease in 5 (7.5%) and progressive disease in 15 (22.4%). Grade III and IV toxicities were infrequent (5%) with no chemotherapy-related mortality. After completion of the treatment, 9 (13.4%) patients were shifted to bladder preservation treatment due to complete radiological response and refusal of surgery. Conclusion: Neoadjuvant chemotherapy is feasible in MIBC patients in our setting as it gives good clinical response. If offered in a proper way, it doesn’t preclude the patients’ chances for definitive treatment.
View on SCiNiTO
Top